Systemic AL amyloidosis with disseminated intravascular coagulation associated with hyperfibrinolysis
暂无分享，去创建一个
[1] M. Skinner,et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. , 2007, Blood.
[2] P. Hawkins,et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. , 2007, Blood.
[3] J. Cavenagh,et al. Guidelines on the diagnosis and management of AL amyloidosis , 2004 .
[4] D. Perry,et al. Factor X deficiency. , 2002, Blood reviews.
[5] P. Hawkins,et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL‐amyloidosis , 2000, British journal of haematology.
[6] P. Cacoub,et al. AL Amyloidosis Combined with Acquired Factor V Deficiency , 1998, Annals of Internal Medicine.
[7] R. Simms,et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. , 1992, American journal of clinical pathology.
[8] Takuo Sato,et al. Nafamostat mesilateと各種セリン蛋白分解酵素阻害剤のIn vitroにおける作用の比較研究 , 1986 .
[9] Kyle Ra,et al. Amyloidosis (AL). Clinical and laboratory features in 229 cases. , 1983 .
[10] J. Valdin,et al. Increased fibrinolysis and amyloidosis. , 1983, Archives of internal medicine.
[11] T. Astrup,et al. Enhanced Blood Coagulation and Fibrinolysis in a Patient with Primary Amyloidosis , 1971, Thrombosis and Haemostasis.